Robot-assisted versus open surgery for radical nephrectomy with level 1-2 vena cava tumor thrombectomy: a French monocenter experience (UroCCR study #73).


Journal

Minerva urology and nephrology
ISSN: 2724-6442
Titre abrégé: Minerva Urol Nephrol
Pays: Italy
ID NLM: 101777299

Informations de publication

Date de publication:
08 2021
Historique:
pubmed: 18 11 2020
medline: 26 11 2021
entrez: 17 11 2020
Statut: ppublish

Résumé

The aim of this paper was to assess the feasibility of robot-assisted radical nephrectomy (RN) with inferior vena cava thrombectomy (RRVCT) and compare perioperative and oncological outcomes of this approach to open surgery for renal tumors with level 1-2 inferior vena cava (IVC) thrombus. We performed a retrospective analysis of patients surgically treated for renal cancer with IVC level 1-2 thrombus in the Urology department of Bordeaux University Hospital between December 2015 and December 2019. Patients were stratified by surgical approach in two groups: open vs. robotic procedures. Pre-, per- and postoperative data were collected within the framework of the UroCCR project (NCT03293563). Univariate and multivariate analysis using regression models were performed. A total of 40 patients underwent RN with IVC tumor thrombus. Open and robotic surgery represented respectively 30 and 10 cases. The two groups were comparable regarding pre-operative tumor and patient characteristics. Robotic procedures were associated with lower estimated blood loss (EBL) (500 vs. 1250 mL, P=0.02), shorter Intensive Care Unit stay (2 vs. 4 days, P=0.03) and decrease of global length of stay (LOS) (7 vs. 10 days, P<0.01). Operative Time (OT) was significantly longer in the robotic group (350.5 vs. 208 min, P<0.01). No difference were observed between the two approaches regarding complications and oncological outcomes. Robotic approach induced lower bleeding and shorter LOS but required longer OT. This technique is feasible and safe for selected cases and experimented surgical teams. Complications rate and oncological outcomes are not different compared to standard open procedures.

Sections du résumé

BACKGROUND
The aim of this paper was to assess the feasibility of robot-assisted radical nephrectomy (RN) with inferior vena cava thrombectomy (RRVCT) and compare perioperative and oncological outcomes of this approach to open surgery for renal tumors with level 1-2 inferior vena cava (IVC) thrombus.
METHODS
We performed a retrospective analysis of patients surgically treated for renal cancer with IVC level 1-2 thrombus in the Urology department of Bordeaux University Hospital between December 2015 and December 2019. Patients were stratified by surgical approach in two groups: open vs. robotic procedures. Pre-, per- and postoperative data were collected within the framework of the UroCCR project (NCT03293563). Univariate and multivariate analysis using regression models were performed.
RESULTS
A total of 40 patients underwent RN with IVC tumor thrombus. Open and robotic surgery represented respectively 30 and 10 cases. The two groups were comparable regarding pre-operative tumor and patient characteristics. Robotic procedures were associated with lower estimated blood loss (EBL) (500 vs. 1250 mL, P=0.02), shorter Intensive Care Unit stay (2 vs. 4 days, P=0.03) and decrease of global length of stay (LOS) (7 vs. 10 days, P<0.01). Operative Time (OT) was significantly longer in the robotic group (350.5 vs. 208 min, P<0.01). No difference were observed between the two approaches regarding complications and oncological outcomes.
CONCLUSIONS
Robotic approach induced lower bleeding and shorter LOS but required longer OT. This technique is feasible and safe for selected cases and experimented surgical teams. Complications rate and oncological outcomes are not different compared to standard open procedures.

Identifiants

pubmed: 33200900
pii: S0393-2249.20.04052-7
doi: 10.23736/S2724-6051.20.04052-7
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

498-508

Auteurs

Nam-Son Vuong (NS)

Department of Urology, Bordeaux University Hospital, Bordeaux, France - dr.nsvuong@gmail.com.

Jean-Marie Ferriere (JM)

Department of Urology, Bordeaux University Hospital, Bordeaux, France.

Clément Michiels (C)

Department of Urology, Bordeaux University Hospital, Bordeaux, France.

Laura Calen (L)

Department of Urology, Bordeaux University Hospital, Bordeaux, France.

Lorenso Tesi (L)

Department of Urology, Bordeaux University Hospital, Bordeaux, France.

Grégoire Capon (G)

Department of Urology, Bordeaux University Hospital, Bordeaux, France.

Henri Bensadoun (H)

Department of Urology, Bordeaux University Hospital, Bordeaux, France.

Eric Alezra (E)

Department of Urology, Bordeaux University Hospital, Bordeaux, France.

Vincent Estrade (V)

Department of Urology, Bordeaux University Hospital, Bordeaux, France.

Grégoire Robert (G)

Department of Urology, Bordeaux University Hospital, Bordeaux, France.

Franck Bladou (F)

Department of Urology, Bordeaux University Hospital, Bordeaux, France.

Jean-Christophe Bernhard (JC)

Department of Urology, Bordeaux University Hospital, Bordeaux, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH